Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

MorphoSys and Celgene end collaboration

Country: Germany

MorphoSys has regained rights from Celgene Corp to an experimental antibody for patients with multiple myeloma following the termination of a co-development and co-promotion agreement between the two companies.

Read more

OSE Pharma raises €21.1 million with IPO

Country: France

France’s OSE Pharma SA, which is developing immunotherapies for cancer, has raised €21.1 million with an initial public offering of its shares on the Euronext stock exchange in Paris. The managers said the IPO was 3.6 times oversubscribed.

Read more

New venture funding for Rigontec

Country: Germany

Read more

Evotec reports loss for 2014

Country: Germany

Read more

SkyePharma outlines investment plans

Country: United Kingdom

Read more

EUSA Pharma is reborn

Country: United Kingdom

Read more

Change continues at Zealand Pharma

Country: Denmark

Read more

Outcomes study of Lyxumia completes

Country: France

Read more

Zerhouni calls for regulatory convergence

Country: United Kingdom

Read more

ArGEN-X advances lead antibody

Country: Belgium

Read more

Meeting Report: Focus on cell therapy

Country: France

Read more

Gates makes equity investment in CureVac

Country: United States

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

The story behind Europe's first stem-cell therapy

HoloclarStoryMar15.pdf

Highlights of the March 2015 MedNous issue

The March 2015 MedNous features:

Latest Mednous cover
  • Regenerative Medicine
    The story behind Europe’s first stem-cell therapy
  • Oncology Review
    A window onto oncology drug success rates
    By Bruno Pagliara
  • Business Strategy
    Measuring how drugs bind to their targets
    Interview with Michael Dabrowski
  • Commentary
    The case for drug rediscovery
    by John Lisman
  • Commentary
    Designing new drugs against complex targets
    by Arthur Oubrie

The latest MedNous journal. Subscribe to download.